The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Ben J.L. Van den Branden

Showing 1-8 of 8 articles
Interventions for valvular disease
Impact of mitral valve treatment choice on mortality according to aetiology
Kortlandt F, Velu J, Schurer R, Van den Branden B, Bouma B, Kelder J, Eefting F, Swaans M, Rensing B, Baan Jr J, Van der Heyden J
April 16, 2019 | 10.4244/EIJ-D-18-00874
Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions
Teeuwen K, Van den Branden B, Koolen J, van der Schaaf R, Henriques J, Thijssen J, Kelder J, Vermeersch P, Rensing B, Suttorp MJ
March 20, 2015 | 10.4244/EIJY14M08_07
Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions
Van den Branden B, Teeuwen K, Koolen J, van der Schaaf R, Henriques J, Thijssen J, Kelder J, Vermeersch P, Rensing B, Suttorp MJ
November 29, 2013 | 10.4244/EIJV9I7A138
Late catch-up in lumen diameter at five-year angiography in MACE-free patients treated with sirolimus-eluting stents in the Primary Stenting of Totally Occluded Native Coronary Arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II)
Teeuwen K, Van den Branden B, Rahel B, Laarman G, Thijssen J, Kelder J, Slagboom T, ten Berg J, Suttorp MJ
June 28, 2013 | 10.4244/EIJV9I2A36
Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II study)
Van den Branden B, Rahel B, Laarman G, Slagboom T, Kelder J, ten Berg J, Suttorp MJ
February 21, 2012 | 10.4244/EIJV7I10A190
The BioSTAR® device versus the CardioSEAL® device in patent foramen ovale closure: comparison of mid-term efficacy and safety
Van den Branden B, Luermans J, Post M, Plokker H, ten Berg J, Suttorp MJ
September 30, 2010
Re-examining minimal luminal diameter relocation and quantitative coronary angiography - intravascular ultrasound correlations in stented saphenous vein grafts: methodological insights from the randomised RRISC trial
Semeraro O, Agostoni P, Verheye S, van Langenhove G, Van den Heuvel P, Convens C, Van den Branden B, Bruining N, Vermeersch P
March 20, 2009
One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with <i>de novo</i> native coronary artery lesions: the SPIRIT II study
Ruygrok P, Desaga M, Van den Branden B, Rasmussen K, Suryapranata H, Dorange C, Veldhof S, Serruys P
November 20, 2007

Latest news

NEW ISSUE
CTOs, next-day discharge after TAVI, ViV, cerebral embolic protection, TMVR
August 7, 2020
New
Ahead of Print: Transcatheter mitral replacement after AVR
August 13, 2020
Editorial
"Minimalist” TAVI during the COVID-19 pandemic: previously optional but now a necessity
D. Wood
August 13, 2020
Guidance Papers
Guidelines, consensus & position papers
June 25, 2020
PCR Trials
TWILIGHT, ONYX ONE, DKCRUSH-V and much more
(The Trials book is supported by Biotronik)
August 11, 2020
Editorial
IVUS for guidance of coronary interventions: applying optimisation targets to improve clinical outcomes
K. Koskinas
August 13, 2020
JAA
This Week's JAA's: Real-world Use of the Evolut PRO Valve...
August 4, 2020
Coronary
Valvular disease
Heart failure
Peripheral
Hypertension
Stroke